A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

Ведущий спонсор: Janssen Research & Development, LLC

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).

SLE is a complex, immune-mediated inflammatory disorder of unknown etiology that can affect almost any organ system and follows a waxing and waning disease course. In SLE, the immune system attacks the body cells and tissues and the resulting inflammation and tissue damage can harm the heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous system. Nipocalimab is a fully human aglycosylated immunoglobulin (Ig)G1 monoclonal antibody designed to selectively bind, saturate, and block the IgG binding site on the endogenous neonatal fragment crystallizable receptor (FcRn). Thus, nipocalimab, a FcRn antibody, has potential in treatment of SLE through lowering of pathogenic IgGs and immune complexes. The study will consist of a Screening Period (less than or equal to [<=] 6 Weeks), double-blind Treatment Period (52 Weeks), and a Follow-up Period (6 Weeks). Key safety assessments will include adverse events (AEs), serious adverse events (SAEs), adverse events of special interests (AESIs), clinical laboratory tests (hematology, chemistry, urinalysis, and lipid profile) and vital signs. The total duration of the study is up to 64 weeks.

• Systemic Lupus Erythematosus

Тип вмешательства: Other

Название вмешательства: Placebo

Описание: Placebo will be administered intravenously.

Этикетка Arm Group: Group 1: Placebo

Тип вмешательства: Drug

Название вмешательства: Nipocalimab

Описание: Nipocalimab dose 1 and dose 2 will be administered intravenously.

Тип вмешательства: Drug

Название вмешательства: Standard-of-care treatment

Описание: Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.

Критерии:

Inclusion Criteria: - Has a clinical diagnosis of systemic lupus erythematosus (SLE) greater than or equal to (>=) 6 months prior to the screening visit and according to Systemic Lupus International Collaborating Clinics (SLICC)-2012 classification criteria: at least 4 criteria fulfilled, with at least 1 clinical criterion and 1 immunologic criterion - Has at least 1 BILAG (british isles lupus assessment group) A and/or 2 BILAG B scores observed during screening - Must have at least moderately active SLE, as defined as systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) score >= 6 at screening visit. Must also have SLEDAI 2K >= 4 for clinical features (that is, SLEDAI-2K score excluding headache and laboratory abnormalities) present at Week 0 prior to randomization - Has a CLASI (cutaneous lupus erythematosus disease area and severity index) activity score of at least 6 (excluding diffuse non-inflammatory alopecia) or at least 4 joints with pain and signs of inflammation (active joints) at screening or at Week 0, or both - At least 1 unequivocally positive autoantibody test including antinuclear antibodies (ANA) (>= 1:80) and/or anti-double stranded deoxyribonucleic acid (dsDNA) antibodies (level >= 75 international units/milliliter [IU/mL]) and/or anti-Smith antibodies (>120 Absorbance unit/milliliter [AU/mL]) detected during screening - Must be receiving 1 or more of the following protocol-permitted, systemic standard-of-care treatments prior to first administration of study intervention at a stable dose: oral glucocorticoids, antimalarial or up to 2 immunomodulatory drugs Exclusion Criteria: - Current or history of, severe, progressive, or uncontrolled renal disease, with the exception of active lupus nephritis (LN). Have severe active LN as determined by sponsor (or designee) adjudication - Has any unstable or progressive manifestation of SLE that is likely to warrant escalation in therapy beyond permitted background medications - Has other inflammatory diseases that might confound the evaluations of efficacy - Has a severe infection including opportunistic infections requiring parenteral anti-infectives, and/or hospitalization within 8 weeks prior to screening - Has received a single B-cell targeting agent within 3 months prior to first administration of study intervention

Пол:

All

Минимальный возраст:

18 Years

Максимальный возраст:

65 Years

Здоровые волонтеры:

No

Фамилия: Study Contact

Телефон: 844-434-4210

Argentina

Bulgaria

Colombia

Germany

Hong Kong

Hungary

Japan

Poland

Russian Federation

South Africa

Spain

Taiwan

Ukraine

United States

2022-01-01

Тип: Sponsor

• Lupus
• SLE
• Nipocalimab
• Lupus SLE

• Lupus Erythematosus, Systemic

Метка: Group 1: Placebo

Тип: Placebo Comparator

Описание: Participants will receive placebo intravenously (IV) every two weeks (q2w) through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and Glucocorticoids [GCs]).

Метка: Group 2: Nipocalimab Dose 1

Тип: Experimental

Описание: Participants will receive nipocalimab dose 1 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).

Метка: Group 3: Nipocalimab Dose 2

Тип: Experimental

Описание: Participants will receive nipocalimab dose 2 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).

Распределение: Randomized

Модель вмешательства: Parallel Assignment

Первичное назначение: Treatment

Маскировка: Double (Participant, Investigator)